Effect of sacubitril-valsartan on chronic systolic heart failure and its effect on LVEF, 6-MWT, NT proBNP and NT proBNP/BNP levels

Purpose: To assess the effect of sacubitril-valsartan on chronic heart failure (CHF). Methods: A total of sixty CHF patients were divided randomly into two groups of thirty patients each (conventional and sacubitril-valsartan groups, respectively). Conventional anti-heart-failure treatment was used in the conventional group, while the sacubitril-valsartan group received sacubitril-valsartan (25 mg) taken orally, twice daily, followed by up-titration to 100 mg, twice daily. After 3 months of treatment, the six-minute walking test (6-MWT), left ventricular ejection fraction (LVEF) scores, left ventricular end-diastolic diameters, serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) and NT-proBNP/brain natriuretic peptide (BNP) levels, treatment efficacy, and adverse cardiovascular events were evaluated. Results: After three months of treatment, the level of serum NT-proBNP and NT-proBNP/BNP in the sacubitril-valsartan group was lower, while the levels of LVEF and 6-MWT were higher (p < 0.05), compared with the conventional group. Sacubitril-valsartan treatment had a better therapeutic effect than the conventional treatment, while readmission rate for heart failure was lower in the sacubitril-valsartan treatment group (p < 0.05). Both LVEF and 6-MWT values had significantly negative correlation with NT-proBNP/BNP ratio. Conclusions: The efficacy of sacubitril-valsartan in the treatment of CHF is significant and improves the short-term prognosis of patients. These findings will require validation in large multicentre trials and over a longer duration of study.